Lev Facher

Washington Correspondent

Lev Facher is a Washington Correspondent for STAT, reporting on the politics of health and life sciences. He has written extensively about the federal government's response to the opioid crisis, the pharmaceutical industry's influence on Capitol Hill, and federally funded biomedical research. Lev earned an economics degree from the University of Michigan, where he worked as managing editor of The Michigan Daily. You can reach him via email at lev.facher@statnews.com and by phone/WhatsApp/Signal at (510)-374-8880.

Politics

Lev Facher

Washington Correspondent

Trump says it’s ‘great to see’ Pelosi’s drug pricing plan

Our 9 biggest questions about Nancy Pelosi’s drug pricing bill

Pelosi’s drug pricing plan would let Medicare negotiate prices for up to 250 drugs

Democrats still have questions about Nancy Pelosi’s drug pricing plan

Couple stole trade secrets from U.S. children’s hospital to market their Chinese biotech, prosecutors say

Frontrunner to lead FDA, dogged by controversies, has developed knack for confronting them

Pelosi’s drug pricing plan is more aggressive than expected

As Congress considers lowering drug costs, pharma CEOs target key senators with campaign cash

Surgeon general: Marijuana during pregnancy and adolescence is dangerous

Canadian officials say ‘all options’ on the table in responding to Trump importation plan

Former NFL players with worse or more frequent concussions are more likely to show sexual dysfunction, study shows

In bid to improve care, Trump administration to relax privacy rules for patients with history of addiction

NIH will soon share genetic data with those who participated in precision medicine study

Canadians are hopping mad about Trump’s drug importation plan. Some of them are trying to stop it

Democratic candidates are promising big on lower drug prices. These advisers are helping formulate their plans

‘Don’t be a Bernie Bro’: Inside conservatives’ brazen campaign to sabotage Trump’s signature drug pricing plan

Key Senate committee advances its sweeping drug pricing bill — and keeps caps on price hikes

Senate committee unveils ambitious plan to cap drug price hikes, out-of-pocket expenses